Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caligiuri

Showing results (871-880 of 1,066) with videos related to

Pageof 107
Sort By:
Cancer Discovery|July 17, 2016
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell LymphomaAnjali Mishra, Krista La Perle, Sonya Kwiatkowski, et al.
The American Journal of Pathology|November 14, 2009
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblastsPeter Fickert, Andrea Fuchsbichler, Tarek Moustafa, et al.
Cancer Cell|November 16, 2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinPaolo Neviani, Ramasamy Santhanam, Rossana Trotta, et al.
Targeted Oncology|February 24, 2023
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast CancerMaureen Caligiuri, Grace L Williams, Jennifer Castro, et al.
JCI Insight|February 4, 2025
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitorsMiguel A Villalona-Calero, Lei Tian, Xiaochen Li, et al.
Dalton Transactions (Cambridge, England : 2003)|February 19, 2025
Unlocking the potential of organopalladium complexes for high-grade serous ovarian cancer therapyThomas Scattolin, Enrico Cavarzerani, Dario Alessi, et al.
Blood|March 19, 2005
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapySusan P Whitman, Shujun Liu, Tamara Vukosavljevic, et al.
Blood|December 11, 2012
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathwayYonghui Li, Li Gao, Xufeng Luo, et al.
Nanophotonics (Berlin, Germany)|June 11, 2025
Disordered plasmonic system with dense copper nano-island morphologyTlek Tapani, Vincenzo Caligiuri, Yanqiu Zou, et al.
RSC Advances|May 2, 2025
Influence of the charge of 1,3,5-triaza-7-phosphaadamantane-based ligands on the anticancer activity of organopalladium complexesTommaso Lorenzon, Maria Vescovo, Michele Maiullari, et al.
Pageof 107

Showing results (871-880 of 1,066) with videos related to

Sort By:
Pageof 107
Cancer Discovery|July 17, 2016
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell LymphomaAnjali Mishra, Krista La Perle, Sonya Kwiatkowski, et al.
The American Journal of Pathology|November 14, 2009
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblastsPeter Fickert, Andrea Fuchsbichler, Tarek Moustafa, et al.
Cancer Cell|November 16, 2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinPaolo Neviani, Ramasamy Santhanam, Rossana Trotta, et al.
Targeted Oncology|February 24, 2023
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast CancerMaureen Caligiuri, Grace L Williams, Jennifer Castro, et al.
JCI Insight|February 4, 2025
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitorsMiguel A Villalona-Calero, Lei Tian, Xiaochen Li, et al.
Dalton Transactions (Cambridge, England : 2003)|February 19, 2025
Unlocking the potential of organopalladium complexes for high-grade serous ovarian cancer therapyThomas Scattolin, Enrico Cavarzerani, Dario Alessi, et al.
Blood|March 19, 2005
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapySusan P Whitman, Shujun Liu, Tamara Vukosavljevic, et al.
Blood|December 11, 2012
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathwayYonghui Li, Li Gao, Xufeng Luo, et al.
Nanophotonics (Berlin, Germany)|June 11, 2025
Disordered plasmonic system with dense copper nano-island morphologyTlek Tapani, Vincenzo Caligiuri, Yanqiu Zou, et al.
RSC Advances|May 2, 2025
Influence of the charge of 1,3,5-triaza-7-phosphaadamantane-based ligands on the anticancer activity of organopalladium complexesTommaso Lorenzon, Maria Vescovo, Michele Maiullari, et al.
Pageof 107